Advertisement

Indian Journal of Clinical Biochemistry

, Volume 30, Issue 4, pp 412–417 | Cite as

The Relationship Between Adropin Levels and the Slow Coronary Flow Phenomenon

  • Bora DemircelikEmail author
  • Alparslan Kurtul
  • Hakan Ocek
  • Muzaffer Cakmak
  • Mustafa Cetin
  • Cagın Ureyen
  • Beyhan Eryonucu
Original Article

Abstract

There is accumulating evidence that inflammation plays a major role in the development of the slow coronary flow (CSF) phenomenon. In this study, we aimed to study the new biomarker adroin levels as it relates to CSF. Patients who underwent coronary angiography before and had no significant epicardial coronary disease were included in the study. Patients who had thrombolysis in myocardial infarction frame counts (TFCs) above the normal cutoffs were considered to have CSF and those within normal limits were considered to have normal coronary flow (NCF). NCF group over the age of 30 were selected from patients with normal coronary arteries. The adropin levels and biochemical profiles of all patients were studied and analyzed with coronary flow parameters. There were 58 patients in the CSF group and 50 patients in the NCF group. The mean adropin level was significantly lower in CSF group than in NCF group (3.2 ± 0.71 vs. 4.9 ± 1.51 ng/mL, p < 0.001).There was a significant correlation between the adropin levels and TFC (r = −0.676, p < 0.001). Multivariable regression analysis showed that the adropin levels were an independent predictor of the CSF phenomenon (odds ratio = 1.041, 95 % confidence interval: 1.004–1.114, p = 0.014). In this study, we show that patients with CSF have decreased levels of adropin. We further show a strong correlation between the adropin levels and coronary blood flow. We conclude that decreased adropin levels might be a useful tool in predicting CSF in patients who undergo coronary angiography.

Keywords

Adropin Inflamation Coronary slow flow 

Notes

Conflict of Interest

None.

References

  1. 1.
    Dogan M, Akyel A, Cimen T, Bilgin M, Sunman H, Kasapkara HA et al. Relationship between neutrophil to lymphocyte ratio and slow coronary flow. Clin Appl Thromb Hemost. 2013 Jul 26. [Epub ahead of print].Google Scholar
  2. 2.
    Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries: a new angiographic finding. Am Heart J. 1972;84(1):66–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis. 2003;14(2):155–61.CrossRefPubMedGoogle Scholar
  4. 4.
    Cin VG, Pekdemir H, Camsar A, Ciçek D, Akkus MN, Parmaksýz T, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J. 2003;44(6):907–19.CrossRefPubMedGoogle Scholar
  5. 5.
    Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small vessel coronary artery disease in patients with ang&inodot;na pectoris and patent large coronary arteries. Circulation. 1986;74(5):964–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Kalay N, Aytekin M, Kaya MG, Ozbek K, Karayakalı M, Söğüt E, et al. The relationship between inflammation and slow coronary flow: increased red cell distribution width and serum uric acid levels. Turk Kardiyol Dern Ars. 2011;39(6):463–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Turhan H, Saydam GS, Erbay AR, Ayaz S, Yasar AS, Aksoy Y, et al. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol. 2006;108(2):224–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122:S185–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Kathir K, Adams MR. Endothelial dysfunction as a predictor of acute coronary syndromes. Semin Vasc Med. 2003;3(4):355–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2013;9:1–8.Google Scholar
  11. 11.
    Yilmaz MB, Balbay Y, Caldir V, Ayaz S, Guray Y, Guray U, et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res. 2005;115:25–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879–88.CrossRefPubMedGoogle Scholar
  13. 13.
    Isik T, Ayhan E, Uyarel H, Ergelen M, Tanboga IH, Kurt M, et al. Increased mean platelet volume associated with extent of slow coronary flow. Cardiol J. 2012;19:355–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Gokce M, Kaplan S, Tekelioglu Y, Erdogan T, Kucukosmanoglu M. Platelet function disorder in patients with coronary slow flow. Clin Cardiol. 2005;28(3):145–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Pekdemir H, Cin VG, Cicek D, Camsari A, Akkus N, Döven O, et al. Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol. 2004;59(2):127–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Yucel H, Ozaydin M, Dogan A, Erdogan D, Icli A, Sutcu R. Evaluation of plasma oxidative status in patients with slow coronary flow. Kardiol Pol. 2013;71(6):588–94.CrossRefPubMedGoogle Scholar
  17. 17.
    Barutcu I, Sezgin AT, Sezgin N, Gullu H, Esen AM, Topal E, et al. Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow. Angiology. 2007;58(4):401–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Li JJ, Qin XW, Li ZC. Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta. 2007;385(1–2):43–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Kuloglu T, Aydin S. Immunohistochemical expressions of adropin and inducible nitric oxide synthase in renal tissues of rats with streptozotocin-ınduced experimental diabetes. Biotech Histochem. 2014;89(2):104–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol. 2002;53:503–14.PubMedGoogle Scholar
  21. 21.
    Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk asystematic review and metaanalysis. J Am Coll Cardiol. 2010;56:1113–32.CrossRefPubMedGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2014

Authors and Affiliations

  • Bora Demircelik
    • 1
    Email author
  • Alparslan Kurtul
    • 2
  • Hakan Ocek
    • 2
  • Muzaffer Cakmak
    • 3
  • Mustafa Cetin
    • 4
  • Cagın Ureyen
    • 5
  • Beyhan Eryonucu
    • 1
  1. 1.Department of CardiologyTurgut Ozal UnıversityAnkaraTurkey
  2. 2.Department of CardiologyAnkara Education and Research HospitalAnkaraTurkey
  3. 3.Department of Internal MedicineTurgut Ozal UnıversityAnkaraTurkey
  4. 4.Department of CardiologyAnkara Numune Education and Research HospitalAnkaraTurkey
  5. 5.Department of CardiologyAntalya Education and Research HospitalAntalyaTurkey

Personalised recommendations